North America Contrast Media Market, by Product Type, by Application, by Modality, by Country, Industry Analysis and Forecast, 2019 - 2025

The North America Contrast Media Market is expected to witness market growth of 2.91% CAGR during the forecast period (2019-2025).

The first contrast agent based on gadolinium had been approved in the United States. Over the past decade, four agents have been licensed in the U.S. and they have set a stringent trend in the industry to continue finding more efficient, reliable, and safe agents. In the coming years, the contrast media revenues are projected to rise in the USA. Sales of contrast media for the ultrasound market might have a significant growth rate among the various imaging modalities. The United States is North America's biggest consumer market for contrast media.

Contrast media is used to enhance the body's internal images created by ultrasound, MRI, x-ray and CT scans. This helps the radiologists to distinguish between normal and abnormal tissues. They're not the dyes that permanently discolor the internal organs. Rather, they are the substances that temporarily change how imaging devices communicate with the body. These help to distinguish the chosen body areas from the surrounding tissue and thus enhance the visibility of different tissues, blood vessels, and organs.

Market growth can be attributed to the oligopolistic existence of the contrast media market. Main companies such as Bayer, GE Healthcare, Guerbet, Lantheus Medical Imaging, and Bracco Diagnostics have a substantial market share for clinical trials. Through indication extension approaches in major countries such as the U.S., these businesses aim for a greater share. They target niche patient cohorts with approvals for unique conditions and raise the degree of product adoption.

Based on Product Type, the market is segmented into Iodinated, Barium-based, Gadolinium-based and Microbubble. Based on Application, the market is segmented into Neurological disorders, Cancer, Cardiovascular disorders, Gastrointestinal disorders, Nephrological disorders, Musculoskeletal disorders and Other Applications. Based on Modality, the market is segmented into X-ray/CT, MRI and Ultrasound. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, General Electric (GE) Co. (GE Healthcare), The Guerbet Group, Lantheus Holdings, Inc., Bracco S.p.A., Trivitron Healthcare Pvt. Ltd., Nano Therapeutics Pvt. Ltd., Magnus Health, LLC (Veracross LLC), Imax Diagnostic Imaging Limited, and Daiichi Sankyo Company, Limited.

Scope of the Study

Market Segmentation:

By Product Type

• Iodinated
• Barium-based
• Gadolinium-based
• Microbubble

By Application

• Neurological disorders
• Cancer
• Cardiovascular disorders
• Gastrointestinal disorders
• Nephrological disorders
• Musculoskeletal disorders
• Other Applications

By Modality

• X-ray/CT
• MRI
• Ultrasound

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Bayer AG
• General Electric (GE) Co. (GE Healthcare)
• The Guerbet Group
• Lantheus Holdings, Inc.
• Bracco S.p.A.
• Trivitron Healthcare Pvt. Ltd.
• Nano Therapeutics Pvt. Ltd.
• Magnus Health, LLC (Veracross LLC)
• Imax Diagnostic Imaging Limited
• Daiichi Sankyo Company, Limited

Unique Offerings from the Publisher

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free